{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:31:20Z","timestamp":1760146280596,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Biologics are a cornerstone in the treatment of severe cases of inflammatory bowel disease (IBD) and aim to control the disease and improve quality of life. This study investigated changes in nonbiologic medication prescriptions for IBD patients initiating biologic therapy in Germany. Methods: This study used data from anonymized pharmacy records in the German longitudinal prescription (LRx) database and included biologic-naive IBD patients who received their first biologic therapy prescription between 2016 and 2022. Changes in prescription rates and pill counts for nonbiologic medications (corticosteroids, 5-aminosalicylates (5-ASA), proton pump inhibitors, analgesics, immunosuppressants, Vitamin D, iron, and antibiotics) before and after the initiation of biologic therapy were assessed using descriptive statistics, McNemar\u2019s tests, and Poisson regression models, adjusting for age and sex. Results: A total of 29,559 biologic-naive IBD patients were included. Prior to index, 91.2% received at least one nonbiologic medication prescription, where corticosteroids and 5-ASA were the most common. Postindex, the overall prescription rate decreased to 87.7%, with significant reductions in prescriptions observed for corticosteroids, 5-ASA, and immunosuppressants (p-values &lt; 0.001). The mean (SD) pill count dropped from 704 (1712) to 514 (1651), with the largest mean differences (95% CI) having been for corticosteroids (\u221277.9 [\u221280.3 to \u221275.5]), 5-ASA (\u221261.6 [\u221265.2 to \u221258.1]), and immunosuppressants (\u221255.0 [\u221257.5 to \u221252.6]). Older patients tended to have greater decreases in pill counts for corticosteroids and 5-ASA, while males showed statistically significant reductions in pill count for immunosuppressants compared with females. Conclusions: This study demonstrates that the prescription of nonbiologic medications significantly decreased after biologic therapy initiation. The use of biologics may therefore lead to improved disease management and potentially better patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm13216408","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T10:50:08Z","timestamp":1729853408000},"page":"6408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"13","author":[{"given":"Annika","family":"Fernandez Milano","sequence":"first","affiliation":[{"name":"Epidemiology, IQVIA, 60549 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Krieg","sequence":"additional","affiliation":[{"name":"Department of Inclusive Medicine, University Hospital Ostwestfalen-Lippe, Bielefeld University, 33617 Bielefeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7227","authenticated-orcid":false,"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[{"name":"Epidemiology, IQVIA, 60549 Frankfurt, Germany"},{"name":"University Clinic, Philipps-University, 35043 Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/gutjnl-2019-320065","article-title":"Big data in IBD: Big progress for clinical practice","volume":"69","author":"Madgwick","year":"2020","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: Clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1055\/a-0538-3715","article-title":"Chronisch-entz\u00fcndliche Darmerkrankungen: Diagnostik und Therapie in der Praxis","volume":"113","author":"Teich","year":"2018","journal-title":"DMW\u2014Dtsch. Med. Wochenschr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_6","unstructured":"Sternkopf, J., Bokemeyer, B., Tappe, U., and Schultz, C. (2016). Potenziale einer Integrierten Versorgung. Dtsch. \u00c4rztebl., 85."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0028-1109059","article-title":"Die direkten Kosten der Versorgung von Patienten mit Morbus Crohn aus der Perspektive der Gesetzlichen Krankenversicherung","volume":"47","author":"Prenzler","year":"2009","journal-title":"Z. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-0029-1244848","article-title":"Kosten der Colitis ulcerosa\u2014Eine Kalkulation aus der Perspektive der Gesetzlichen Krankenversicherung","volume":"135","author":"Prenzler","year":"2010","journal-title":"DMW\u2014Dtsch. Med. Wochenschr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11377-007-0113-6","article-title":"CED-Behandlung in Deutschland: Betrachtungen zur sinnvollen Vernetzung","volume":"2","author":"Bokemeyer","year":"2007","journal-title":"Gastroenterologe"},{"key":"ref_10","unstructured":"Stallmach, A., H\u00e4user, W., L\u2019hoest, H., and Marschall, U. (2012). Die chronisch entz\u00fcndlichen Darmerkrankungen Morbus Crohn und Colitis ulcerosa. BARMER GEK Gesundheitswesen Aktuell 2012, BARMER."},{"key":"ref_11","first-page":"2957","article-title":"Status quo und was die Zukunft bringen kann","volume":"104","author":"Farrag","year":"2023","journal-title":"Dtsch. \u00c4rztebl"},{"key":"ref_12","first-page":"4","article-title":"Chronisch entz\u00fcndliche Darmerkrankungen: Tipps f\u00fcr eine differenzierte Biologika-Auswahl","volume":"118","author":"Bokemeyer","year":"2021","journal-title":"Dtsch. \u00c4rztebl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7247238","DOI":"10.1155\/2019\/7247238","article-title":"A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0032-1330572","article-title":"Integrierte Versorgung von Patienten mit chronisch-entz\u00fcndlichen Darmerkrankungen im Rhein-Main-Gebiet: Ergebnisse der ersten integrierten Versorgung CED in Deutschland","volume":"51","author":"Blumenstein","year":"2013","journal-title":"Z. Gastroenterol."},{"key":"ref_16","unstructured":"Keiner, D. (2024, April 28). Chronisch Entz\u00fcndet. Available online: https:\/\/www.deutsche-apotheker-zeitung.de\/daz-az\/2019\/daz-20-2019\/chronisch-entzuendet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.12616","article-title":"Systematic review with meta-analysis: Inflammatory bowel disease in the elderly","volume":"39","author":"Gisbert","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11377-022-00661-4","article-title":"Therapieupdate 2022: Colitis ulcerosa","volume":"18","author":"Hoffmann","year":"2023","journal-title":"Gastroenterologie"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ecco-jcc\/jjv188","article-title":"Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases\u2014A Prospective Study on Incidence and Severity","volume":"10","author":"Teich","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_20","first-page":"768","article-title":"Treatment strategies in inflammatory bowel diseases","volume":"120","author":"Stallmach","year":"2023","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12325-016-0441-3","article-title":"Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study","volume":"34","author":"Michetti","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000358135","article-title":"Have Biologics Changed the Natural History of Crohn\u2019s Disease?","volume":"32","author":"Mandel","year":"2014","journal-title":"Dig. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.2006.103564","article-title":"Risks and benefits of biologic therapy for inflammatory bowel diseases","volume":"56","year":"2007","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.phrs.2024.107074","article-title":"Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project","volume":"200","author":"Ingrasciotta","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"otab011","DOI":"10.1093\/crocol\/otab011","article-title":"Persistence with Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis","volume":"3","author":"Mahlich","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/13696998.2019.1707210","article-title":"Living with ulcerative colitis in Germany: A retrospective analysis of dose escalation, concomitant treatment use and healthcare costs","volume":"23","author":"Dignass","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5414\/CP204485","article-title":"German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations","volume":"62","author":"Kostev","year":"2024","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ler, D., Kostev, K., Peters, M., Zamfir, C., Wolk, A., Roderburg, C., and Loosen, S.H. (2022). Machine Learning Can Predict the Probability of Biologic Therapy in Patients with Inflammatory Bowel Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154586"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1055\/a-0903-2938","article-title":"Real-world biologic treatment and associated cost in patients with inflammatory bowel disease","volume":"57","author":"Brandes","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_30","first-page":"910","article-title":"Chronic steroid use: An overlooked impact on patients with inflammatory bowel disease","volume":"6","author":"Farraj","year":"2022","journal-title":"JGH Open Open Access J. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: A randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00605","DOI":"10.14309\/ctg.0000000000000605","article-title":"Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients with Inflammatory Bowel Disease","volume":"14","author":"Peterson","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41395-018-0144-2","article-title":"No Benefit of Concomitant 5-Aminosalicylates in Patients with Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data from Clinical Trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.cgh.2018.11.062","article-title":"Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab","volume":"17","author":"Ma","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00384-019-03368-1","article-title":"Comparison of outcomes of continuation\/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease","volume":"34","author":"Choi","year":"2019","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/apt.14023","article-title":"Systematic review with meta-analysis: Use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease","volume":"45","author":"Bonovas","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/a-0824-0861","article-title":"Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS): AWMF Registry 021\/009","volume":"57","author":"Kucharzik","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.crohns.2010.12.012","article-title":"Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: A subgroup analysis of a large multi-centre, prospective, internet-based study","volume":"5","author":"Blumenstein","year":"2011","journal-title":"J. Crohns Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1751-2980.13026","article-title":"Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis","volume":"22","author":"Chen","year":"2021","journal-title":"J. Dig. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cgh.2018.11.003","article-title":"Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ibd\/izy313","article-title":"A Practical Guide to the Safety and Monitoring of New IBD Therapies","volume":"25","author":"Click","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn\u2019s Disease Patients in Long-term Remission on Azathioprine","volume":"128","author":"Mary","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_44","first-page":"A100","article-title":"P90 Tailoring the need for combination immunosuppressive therapy in IBD patients initiating anti-TNF agents using pre-biologic HLA-DQA1*05 screening: A prospective study","volume":"72","author":"Gonzalez","year":"2023","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"595970","DOI":"10.1155\/2012\/595970","article-title":"High Prevalence but Insufficient Treatment of Iron-Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results of a Population-Based Cohort","volume":"2012","author":"Ott","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mahadea, D., Adamczewska, E., Ratajczak, A.E., Rychter, A.M., Zawada, A., Eder, P., Dobrowolska, A., and Krela-Ka\u017amierczak, I. (2021). Iron Deficiency Anemia in Inflammatory Bowel Diseases\u2014A Narrative Review. Nutrients, 13.","DOI":"10.3390\/nu13114008"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cyto.a.20512","article-title":"Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-\u03b1 transgenic mice","volume":"73A","author":"Capocasale","year":"2008","journal-title":"Cytometry A"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.dld.2019.11.019","article-title":"Effects of anti\u2013TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease","volume":"52","author":"Lucendo","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1136\/gutjnl-2020-321609","article-title":"The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: A patient-level meta-analysis of randomised controlled studies","volume":"70","author":"Lu","year":"2021","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjad070","article-title":"Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: A Report from the epi-IIRN","volume":"17","author":"Gorelik","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1024\/0300-9831\/a000764","article-title":"The use of vitamin D for patients with inflammatory bowel diseases A systematic review","volume":"94","author":"Matias","year":"2022","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1053\/j.gastro.2021.08.060","article-title":"How Should Pain, Fatigue, and Emotional Wellness Be Incorporated into Treatment Goals for Optimal Management of Inflammatory Bowel Disease?","volume":"162","author":"Keefer","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:20:52Z","timestamp":1760113252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":55,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216408"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216408","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}